Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9193 - 9200 of 11616 results
SEC Adopts Regulation A+: New Registration Option For Small and Mid-Sized Companies
March 26, 2015| Blog| Viewpoint
OIG Finds Exclusive Lab Arrangement May Violate Anti-Kickback Statute
March 26, 2015| Blog| Viewpoint
2015 Employment Law Issues Tournament: Sweet Sixteen Results and Recaps
March 25, 2015| Blog| Viewpoint
Supreme Court to Hear Argument on March 31 Whether to Overrule Brulotte v. Thys, Co.
March 25, 2015| Blog| Viewpoint
The FCC and the Uncertain Future of Privacy Oversight for Internet Service Providers
March 25, 2015| Blog| Viewpoint
Supreme Court Holds That Issuers Can Be Liable for Omitting Material Facts From Statements of Opinion in Omnicare Case
March 25, 2015| Blog| Viewpoint
USITC Declines to Institute Investigation of Induced Patent Infringement as Unfair Method of Competition or Unfair Acts
March 24, 2015| Blog| Viewpoint
Mintz Attorneys to Discuss 340B Program, Overpayments and Stark Self-Disclosures at AHLA Medicare & Medicaid Institute
March 24, 2015| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.